A clinical decision aid for the selection of antithrombotic therapy for the prevention of stroke due to atrial fibrillation

European Heart Journal

Volumn 33, Issue 17, 2012, Pages 2163-2171

  Lahaye, Stephen Andrew ^a   Gibbens, Sabra Lynn ^a   Ball, David Gerald Andrew ^a   Day, Andrew George ^a   Olesen, Jonas Bjerring ^b   Skanes, Allan Cameron ^c  

^a QUEEN S UNIVERSITY   (Canada)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Anticoagulation; Antithrombotic; Atrial fibrillation; Decision aid; Stroke prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; APIXABAN; CLOPIDOGREL; DABIGATRAN; PLACEBO; RIVAROXABAN; WARFARIN;

ARTICLE; BLEEDING; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CLINICAL RESEARCH; DECISION SUPPORT SYSTEM; HEART ATRIUM FIBRILLATION; HUMAN; MEDICAL EDUCATION; POINT OF CARE TESTING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM; STROKE;

ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; DECISION SUPPORT TECHNIQUES; DRUG COSTS; FIBRINOLYTIC AGENTS; HUMANS; MORPHOLINES; PYRAZOLES; PYRIDONES; RISK ASSESSMENT; STROKE; THIOPHENES;

EID: 84866088694     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehs167     Document Type: Article

References (24)

1. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, LeHeuzey J-Y, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. Circulation 2006;114:e257-e354.
2. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146:857-867. (Pubitemid 351650486)
3. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2009;361:1139-1151.
4. Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FWA, Zhu J, Wallentin L. Apixaban versus warfarin in patients with atrial fibrillation. N Eng J Med 2011; 365:981-992.
5. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KAA, Califf RM and the ROCKET AF Sterring Committee. Riv-aroxaban versus warfarin in nonvalvular atrial fibrillation. N Eng J Med 2011;365: 883-891.
6. Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, Rich MW, Radford MJ. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial fibrillation (NRAF). Am Heart J 2006;151: 713-719. (Pubitemid 43290267)
7. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation. CHEST 2010;138:1093-1100.
8. Lip GYH, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol 2011;57:173-180.
9. Olesen JB, Lip GYH, Hansen PR, Lindharsen J, Ahlehoff O, Andersson C. Bleeding risk in 'real world' patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort. J Thromb Haemost 2011;9: 1460-1467.
10. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke. JAMA 2001;285: 2864-2870.
11. Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach. CHEST 2010;137:263-272.
12. Lip GYH, Frison L, Halperin JL, Lane DA. Identifying patients at high risk for stroke despite anticoagulation. Stroke 2010;41:2731-2738.
13. Olesen JB, Lip GYH, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation. BMJ 2011;342:d124 doi:10.1136/bmj.d124.
14. Cairns JA, Connolly S, McMurtry S, Stephenson M, Talajic M. Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can J Cardiol 2011;27:74-90.
15. Camm AJ, Kirchof P, Lip GYH, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohnloser SH, Kohl P, Le Heuzey J-Y, Ponikowski P, Rutten FH. Guidelines for the management of atrial fibrillation. Europace 2010;12:1360-1420.
16. Canadian Agency for Drugs and Technology for Health. Recommendations for optimal warfarin management for prevention of thromboembolic events in patients with atrial fibrillation. http://cadth.ca/en/products/optimal-use/warfarin- management/reports (9 December 2011).
17. Connolly SJ, Pogue J, Hart RG, Pfeffer M, Hohnloser SH, Chrolavicius S, Yusuf S. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation Clopidogrel Trial with Irbesartran for prevention of Vascular Events (ACTIVE W): a randomized control trial. Lancet 2006;367:1903-1912.
18. Shah SV, Gage BF. Cost effectiveness of dabigatran for stroke prophylaxis in patients with atrial fibrillation. Circulation 2011;123:2562-2570.
19. Clinical Support Systems. AFib.ca: a clinical decision aid for the selection of antith-rombotic therapy for the prevention of stroke due to atrial fibrillation. http://www.afib.ca (23 February 2012).
20. Clinical Support Systems. 'AFib CDA' iPad Application available in the iTunes App Store (23 February 2012).
21. Wann LS, Curtis AB, Ellenbogen KA, Estes NAM III, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM, Jacobs AK. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran). Circulation 2011;123:1144-1150.
22. Gage BF, Cardinalli AB, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med 1996;156:1829-1836. (Pubitemid 26295228)
23. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH, Diener HC, Franzosi MG, Huber K, Reilly P, Varrone J, Yusuf S. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Circulation 2011;123:2363-2372.
24. Schulman S, Anderson DR, Bungard TJ, Jaeger T, Kahn SR, Wells P, Wilson SJ. Direct and indirect costs of management of long-term warfarin therapy in Canada. J Thromb Haemost 2010;8:2192-200.